Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260372 | 1.00 | ALOX5 (0.44) | ALOX5CES2CES1KEAP1TSHR | |
| SCHEMBL24925796 | 0.81 | ALOX5 (0.46) | ALOX5CES2CES1KEAP1TSHR | |
| SCHEMBL11329381 | 0.79 | — | — | |
| SCHEMBL2030838 | 0.79 | ALOX5 (0.47) | ALOX5CES2CES1KEAP1TSHR | |
| SCHEMBL79717 | 0.79 | — | — | |
| SCHEMBL8800920 | 0.78 | ALOX5 (0.43) | ALOX5CES2CES1KEAP1TSHR | |
| SCHEMBL21291340 | 0.78 | ALOX5 (0.40) | ALOX5CES2CES1KEAP1TSHR | |
| SCHEMBL12111131 | 0.78 | ALOX5 (0.40) | ALOX5CES2CES1KEAP1TSHR | |
| SCHEMBL8587037 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL355659 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178359-B | Heterocyclic substitution-based disulfide derivative, preparation method and application thereof | 贵州大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-116178359-A | Heterocyclic substitution-based disulfide derivative, preparation method and application thereof | 贵州大学 | 2023-05-30 | — | — | CN | disclosed |
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | VANDERBILT UNIVERSITY (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2021087193-A1 | PHTHALONITRILE RESINS, METHODS OF MAKING SAME AND COMPOSITIONS THEREOF | HUNTSMAN ADVANCED MATERIALS AMERICAS LLC (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | VANDERBILT UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053378-B2 | Modified phenolic resin, epoxy resin composition containing the same, and prepreg containing the composition | MITSUI CHEMICALS, INC. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20060161008-A1 | Chloromethylation of thiophene, using aqueous concentrated hydrochloric acid, gaseous hydrogen chloride and paraformaldehyde, in the presence of acetone or methyl-ethyl-ketone or methyl-isobutyl-ketone to produce 2-chloro-methyl-thiophene | SANOFI (FR) | 2006-07-20 | — | — | US | disclosed |
| EP-1392672-B1 | CHLOROMETHYLATION OF THIOPHENE | SANOFI AVENTIS (FR) | 2005-05-04 | — | — | EP | disclosed |
| EP-1392672-A1 | CHLOROMETHYLATION OF THIOPHENE | Sanofi-Aventis (FR) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002094806-A1 | CHLOROMETHYLATION OF THIOPHENE | SANOFI-SYNTHELABO (FR) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | ALOX5 1891/4885CES2 2536/4885CES1 849/4885 |
| US-20200253974-A1 | QUINAZOLINE COMPOUNDS AS MODULATORS OF RAS SIGNALING | NRAS, KRAS, MAVS | ALOX5 4040/4885CES2 4609/4885CES1 3908/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | ALOX5 1281/4885CES2 969/4885CES1 651/4885 |
| US-20080161300-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALOX5 1281/4885CES2 969/4885CES1 651/4885 |
| US-20060161008-A1 | Chloromethylation of thiophene, using aqueous concentrated hydrochloric acid, gaseous hydrogen chloride and paraformaldehyde, in the presence of acetone or methyl-ethyl-ketone or methyl-isobutyl-ketone to produce 2-chloro-methyl-thiophene | TPMT, MCCC2, MGMT | ALOX5 1894/4885CES2 341/4885CES1 752/4885 |
| US-11318137-B2 | Quinazoline compounds as modulators of Ras signaling | NRAS, KRAS, MAVS | ALOX5 4040/4885CES2 4609/4885CES1 3908/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | ALOX5 1281/4885CES2 969/4885CES1 651/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | ALOX5 1245/4885CES2 903/4885CES1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.